Epidermal growth factor receptor expression in urinary bladder cancer

Dayalu S. L. Naik, Shashi Sharma, Amitabha Ray, Suresh Hedau
Institute of Cytology and Preventive Oncology, I-7, Sector-39, Noida, India

ABSTRACT

Objective: To evaluate the expression pattern of epidermal growth factor receptor (EGFR) in urinary bladder cancer and its association with human epidermal growth factor receptor 2 (HER2), epidermal growth factor (EGF), interleukin-6 (IL-6), and high risk human papilloma virus (HPV) types 16 and 18.

Materials and Methods: Thirty cases of urothelial carcinoma were analyzed. EGFR, HER2, EGF, and IL-6 expressions in the tissue were evaluated by immunohistochemical staining. For HPV, DNA from tissue samples was extracted and detection of HPV was done by PCR technique. Furthermore, evaluation of different intracellular molecules associated with EGFR signaling pathways was performed by the western blot method using lysates from various cells and tissues.

Results: In this study, the frequencies of immunopositivity for EGFR, HER2, EGF, and IL-6 were 23%, 60%, 47%, and 80%, respectively. No cases were positive for HPV-18, whereas HPV-16 was detected in 10% cases. Overall, expression of EGFR did not show any statistically significant association with the studied parameters. However, among male patients, a significant association was found only between EGFR and HER2.

Conclusions: Overexpression of EGFR and/or HER2, two important members of the same family of growth factor receptors, was observed in a considerable proportion of cases. Precise knowledge in this subject would be helpful to formulate a rational treatment strategy in patients with urinary bladder cancer.

Key words: Epidermal growth factor receptor, human epidermal growth factor receptor 2, human papilloma virus, immunohistochemistry, urinary bladder carcinoma

INTRODUCTION

The bladder is a common site for cancer development in the urinary tract. In India, according to the recent reports of the National Cancer Registry Programme, the overall incidence rate of the urinary bladder cancer is 2.25% (per 100,000 annually): 3.67% among males and 0.83% for females.[1] Urinary bladder cancer ranks ninth in worldwide cancer incidence (approximately 356,000 new cases each year); it is the seventh most common malignancy in men and 17th in women.[2,3] In the United States and Western Europe, the lifetime risk is about 1 in 25 and 1 in 80 for white males and females, respectively. Furthermore, approximately 145,000 patients die from this disease worldwide per year.[2] Majority of bladder tumors originate from transitional epithelium or urothelium, a multi-layered epithelium without squamous cells, which covers the inside of this organ. Epidemiological studies have shown that the cancer predominantly affects the aged males and the presence of mucosal irritants maybe important such as increased urinary excretion of carcinogenic substances and parasitic infestation. A number of factors, e.g., occupational exposure to chemicals, cigarette smoking, and urinary schistosomiasis are associated with increased risk.[3-7] It may be worthwhile to mention that the urinary bladder cancer is the most common malignancy in Egyptian males and has been attributed to schistosomiasis that is linked with squamous cell carcinoma. Interestingly, in recent time in Egypt, incidence of transitional cell carcinoma has been increasing, whereas squamous cell carcinoma has declined.[8] On the other hand, some reports have suggested a risk contributing role of factors like human papilloma virus (HPV) infection, obesity or coffee consumption,[9-11] however, more studies are needed on these issues for definite conclusions.
Cancer progression is associated with dysregulation of the signaling systems of various growth factors and pro-inflammatory cytokines such as epidermal growth factor (EGF), transforming growth factor-β (TGFβ) and interleukin-6 (IL-6).[12-14] Among four members of the family of erbB tyrosine kinase receptors, EGF-receptor (EGFR) and HER2/neu (or c-erbB-2) have been reported to be involved in the pathological processes of several cancers; and ligands like EGF, heparin-binding EGF (HB-EGF), TGFα and amphiregulin can bind to EGFR.[13] It is believed that HER2 has no known ligand; however, heterodimerization of HER2 with EGFR is possible, which probably confers aggressive tumor behaviors.[15] Several signaling molecules may participate in EGFR activation such as phosphatidylinositol-3 kinase (PI3K), extracellular signal regulated kinase (ERK), mitogen-activated protein kinase (MAPK), etc.[16,17][Figure 1a]. Nevertheless, EGFR activation via ligand binding leads to downstream signaling that influences cell proliferation, angiogenesis, invasion and metastasis.[18] It is worth noting that different studies have shown a prognostic significance of EGFR overexpression in tumors of the urinary bladder. Mason et al. reported an association of the EGFR pathway with the bladder cancer risk and survival.[19] Similarly, Kramer et al. found that EGFR expression was associated with poor prognosis in bladder cancer cases.[20] Moreover, the results of a study on Greek subjects showed that simultaneous expression of EGFR and HER2 in transitional cell carcinomas was related to the advanced histological grade and stage of the disease.[21]

Considering the above-mentioned findings, the present study was conducted to evaluate the pattern of EGFR overexpression in urinary bladder cancer tissue and its correlation with related parameters such as HER2/neu, EGF as well as IL-6. Furthermore, efforts were made to detect HPV types 16 and 18 from the aforesaid cancer tissue and their association (if any) with the overexpression of EGFR. In addition, intracellular signaling molecules associated with EGFR were assessed in normal urinary bladder tissue from the experimental animals along with other normal and cancer cells/tissues in order to find out the predominant signaling molecules in normal condition.

MATERIALS AND METHODS

Clinical samples and immunochemical analysis

A total of 30 cases of transitional cell carcinoma of the urinary bladder were included in this study; the tumor tissue samples were collected from a single institute from 2000 to 2005. In the study, tumor cells recognizable as of transitional cell origin were considered, and thus tumors belonged to grade I (n = 12) and grade II (n = 18) were...
included. Among the above-mentioned cases, 24 were male and 6 were female; the mean ages of the patients were 60.97 ± 10.70 years. The immunohistochemical analysis was carried out on paraffin-embedded 5 μm thick tissue sections from tumors on poly-L-lysine coated slides.[22] In brief, tissue sections were incubated with primary antibody against EGFR (Sigma), HER2/c-erbB-2 (Boehringer Mannheim), EGF (Santa Cruz) and IL-6 (Vision Biosystems). Subsequently, sections were incubated with secondary antibody, followed by peroxidase-anti-peroxidase complex (PAP), and finally detection of immunoreactivity by substrate diaminobenzidine (DAB).

**DNA extraction and detection of HPV DNA sequences by Polymerase Chain Reaction**

High molecular weight genomic DNA from tumor tissue samples was isolated using standard Proteinase K digestion, phenol chloroform extraction, and ethanol precipitation method.[23,24] The quality and concentration of DNA was measured on standard spectrophotometric method. For the detection of HPV DNA, most common L1 consensus primers, MY 09/11 primers derived from HPV genome were employed. HPV-16 plasmid DNA as well as HPV-16 positive tumor DNA from uterine cervical cancer patient served as positive controls, whereas HPV negative cell line C33a DNA and HPV negative breast cancer sample served as negative control. Similarly, HPV-18 plasmid DNA and HPV-18 positive cervical tumor DNA were used as positive controls. For negative controls, the same DNA samples, which were used for HPV-16 analysis, were also utilized here. Amplification of β-globin gene served as internal controls to examine quality, integrity and successful amplification of tissue DNA.

**Conventional PCR using L1 consensus MY 09/11, HPV-16 and HPV-18 primers**

Approximately, 100-200 ng genomic DNA was utilized for conventional PCR according to the routinely followed protocol on a DNA Engine Tetrad (MJ Research, USA). Detection of HPV was carried out using consensus primers (MY09/MY11) located within the conserved L1 region of HPV genome (forward primer 5’-GCM CAG GGW CAT AAY AAT GG-3’, reverse primer 5’-CGT CCM ARR GGA WAC TGA TC-3’ where M= A+C, W= A+T, Y= C+T, R= A+G). HPV-16 URR gene sequences (forward primer 5’-TGA GGT ACC ATT GGA TAT TT-3’, reverse primer 5’-TAG CAA AAA GCT GCT TCA CGC-3’), and β-globin gene sequences (forward primer 5’-GAA GAG CCA AGG ACA GGT AC-3’, reverse primer 5’- CAA CTT CAT CCA CGT TAC ACC -3’) were used as internal controls.

Briefly, the method involved a 25-μl reaction mix containing 100-200 ng DNA, 10 mM Tris-Cl (pH 8.4), 50 mM KCl, 1.5 mM MgCl₂, 12.5 μM of each dNTP (dATP, dCTP, dGTP and dTTP), 5 pmoles of each oligonucleotide primer and 0.5 U Taq DNA polymerase (Perkin-Elmer Biosystems, Foster City, CA, USA). The temperature profile used for amplification constituted an initial denaturation at 95°C for 5 min followed by 39 cycles with denaturation at 95°C for 30 sec, annealing at 55°C for 30 sec and extension at 72°C for 30 sec, which was extended for 4-7 min in the final cycle. The oligonucleotide primers were synthesized in an automated Applied Biosystems DNA Synthesizer (Model 381A, Applied Biosystems Inc., Foster City, CA, USA) and HPLC purified.

**Evaluation of intracellular signaling system**

In normal urinary bladder tissue, to evaluate the important signaling molecules that are involved in EGFR system [Figure 1a], we examined different cancer cell lines (ATCC, Manassas, VA, USA) and tissues obtained from experimental animals. In fact, we did a comparative analysis of different signaling molecules, present in the lysates of the abovementioned cells/tissues, with reference to the normal urinary bladder tissue. For this purpose, we assayed MCF-7 and T47-D human breast cancer cells, mouse mammary tissue, LNCaP and PC-3 human prostate cancer cells, TRAMP tumour tissue, SK-OV-3 human ovarian cancer cells, mouse uterine tissue and mouse urinary bladder tissue.

MCF-7 and SK-OV-3 cells were grown in EMEM and McCoy’s 5A medium, respectively. Both T47-D and LNCaP cells were cultured in RPMI-1640 medium, whereas PC-3 cells in F-12K medium. Media were supplemented with fetal bovine serum. Prostate cancer tissue was collected from TRAMP mouse (transgenic adenocarcinoma of the mouse prostate), which develops prostate tumour spontaneously. Furthermore, mammary tissue, urinary bladder tissue and uterine tissue were collected from C57BL6 mice. Lysates from different tissues and cancer cells were analyzed by the western blot method.[26] Except the primary antibodies against p-p38 MAPK, p-p44/42 MAPK, SEK1/MKK4, SAPK/JNK (Cell Signaling), and p-β-catenin (R and D Systems), all antibodies were from Santa Cruz.

**Statistical analysis**

Chi-square and Fisher exact test was employed to see the association between different parameters as suggested by Armitage et al. for small sample size.[27]Besides this, 95% confidence intervals (CI) were also calculated for the prevalence. Statistical software Epi Info version 6 was used for statistical analyses.

**RESULTS AND DISCUSSION**

Immunohistochemical staining exhibited brownish or golden brown color in positive tissue sections; predominantly membrane staining was observed for EGFR and HER2/ neu, whereas EGF and IL-6 showed cytoplasmic staining [Figure 2]. The present study revealed 23% positivity for EGFR and 60% positivity for HER2; whereas 47% and
80% cases were positive for EGF and IL-6, respectively. In this study, overall, no statistical association was found between the expressions of EGFR and HER2, which are two important members of the same family of growth factor receptors [Table 1]. Interestingly, similar studies on patients with cancer of different sites from the same geographical location demonstrated different expression patterns of EGFR and HER2 [Table 2]. Nevertheless, in the current study, neither EGFR nor HER2 did exhibit any correlations with the expression of EGF and IL-6 or presence of HPV-16 [Table 1]. It may be worthwhile to mention that we tried to detect both high risk HPV types 16 and 18, but only 3 cases (10%) were positive for HPV-16 [Figure 3]. However, after division of the patients on the basis of gender, we found a significant association between EGFR and HER2 expressions in male group only ($P < 0.05$).

There are wide variations in the reports of different investigators regarding the frequencies of both EGFR and HER2 expressions in urinary bladder tumors. It has been

### Table 1: Association pattern among the studied parameters in urinary bladder cancer cases

| HER2/neu  | EGF  | IL-6 | HPV-16 |
|----------|------|------|--------|
| (+)      | 6    | 4    | 1      |
| (-)      | 12   | 20   | 2      |
|          | $P=0.19$, $5.5 (0.5-275.5)$ | $P=0.09$, $0.13 (0.0-1.4)$ | $P=1.00$, $1.75 (0.03-38.6)$ |
| HER2/neu | (+)  |      |        |
|          | 7    | 14   | 1      |
|          | $P=0.30$, $0.08 (0.08-2.53)$ | $P=0.12$, $0.2 (0.02-2.18)$ |
| (-)      | 7    | 10   | 2      |
|          | $P=0.66$, $2.0 (0.24-19.79)$ | $P=1.00$, $0.7 (0.05-6.13)$ |
| EGF      | (+)  | 12   | 2      |
|          | $P=0.00$, $0.08 (0.05-6.13)$ | $P=1.00$, $0.7 (0.02-14.03)$ |
| (-)      | 12   | 2    | 1      |
|          | $P=0.69$, $2.5 (0.11-157.7)$ | $P=0.55$, $0.7 (0.02-14.03)$ |
| IL-6     | (+)  | 3    | 2      |
|          | $P=1.00$, Not defined | $P=0.59$, $2.5 (0.11-157.7)$ |

Percentage of over-expression with 95% confidence interval (CI) of the studied parameters. Epidermal growth factor receptor (EGFR): 23.33% (9.93% - 42.28%), human epidermal growth factor receptor 2 (HER2): 60.0% (40.60% - 77.30%), epidermal growth factor (EGF): 46.7% (28.34% - 65.70%), interleukin-6 (IL-6): 80.0% (61.43% - 92.30%), human papilloma virus type16 (HPV-16): 10.0% (2.11% - 26.52%). Figures below the $P$ values show odds ratio (OR) and their 95% CI, respectively. (+): Positive immunohistochemical expression or presence of HPV-16. (-): No expression or negative case.

### Table 2: Percentage of expression of epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) and their correlation in four different cancer sites

| Cancer sites      | Sex | Mean age (in years) | Positive expression | Correlation between EGFR and HER2 | Reference |
|-------------------|-----|---------------------|---------------------|----------------------------------|-----------|
|                   |     |                     | EGFR (%) | HER2 (%) |                        |           |
| Breast            | Male| 44.4±10.95          | 36       | 32       | Not significant        | [22]      |
|                   | Female| 48.6±10.82         | 50       | 26       | $P<0.05^*$             | [22]      |
| Uterine cervix    | Male| 46.4±12.43          | 40       | 32       | Not significant        | [28]      |
|                   | Female| 66.1±8.38         | 30       | 35       | $P<0.05^*$             | [28]      |
| Prostate          | Male| 60.9±10.70          | 23       | 60       | Not significant        | Present study |

*Significant
documented that squamous cell carcinoma of the urinary bladder, which is frequently related to schistosomal etiology and an advanced stage, expresses enhanced levels of EGFR. Guo et al. analyzed 16 cases of squamous cell cancer and all cases were positive for EGFR. However, Khaled et al. assessed 59 schistosomal bladder tumors; EGFR was detected in 66% cases. On the other hand, Wang et al. noticed 27% positivity for EGFR (14 out of 52 cases) in small cell carcinoma of the urinary bladder. In a study that included 67 patients with urethelial carcinomas, EGFR and HER2 were found to be positive in 63% and 22% patients, respectively. Another study on 56 surgical specimens obtained from invasive bladder carcinomas exhibited a higher rate (75%) of EGFR expression.

Like variations in EGFR positivity, differences in the expression rates of HER2 also have been observed among different reports. In a recent study on 40 patients with transitional cell carcinoma of the bladder, Matsubara et al. found that 43% tumors were HER2 positive. On the contrary, Tapia et al. detected only 7% expression of HER2 protein. Like our current study, Caner et al. and Tsai et al. reported positive staining for HER2 in 61% and 58% of bladder cancer cases, respectively. (56,57) On the other hand, de Pinieux et al. documented 23% (15 out of 64 cases) and Coogan et al. observed 26% (14/54) positive HER2 expression in human bladder transitional cell carcinoma. (38,39)

Our analyses were based on 30 cases, which is a limitation of the current study. Probably, for the small number of cases and inclusion of low grade tumors, the frequency of EGFR expression was lower in comparison with other reports. It is worth noting that a substantial number of studies have been carried out on breast cancer in connection with EGFR and HER2 including relevant targeted therapies. There are several parallels between the breast and bladder cancers. For instance, the risk of urinary bladder cancer has been reported to be higher among breast cancer survivors, and breast cancer appears to be a common primary focus for metastases found in the bladder. For both breast and bladder cancers, studies have implicated issues like environmental factors, sex hormones and insulin-like growth factors in the pathological processes. Nevertheless, in comparison to breast cancer, clinical trials with molecularly targeted agents have been few in number and largely unsuccessful in bladder cancer. Interestingly, a number of investigators have identified alterations in components of several signal transduction pathways in bladder cancer, which are also associated to EGFR. Aberrant activation of such pathways like signal transducer and activator of transcription 3 (STAT3), mitogen-activated protein kinase (MAPK), or phosphatidylinositol 3-kinase (PI3K) pathways perhaps plays crucial role in cancer cell growth and survival. Proper evaluation of the complex interconnections among these signaling pathways and the major downstream effectors such as extracellular signal-regulated kinase (ERK) and AKT will greatly improve our understanding for better diagnosis and management. Several investigators have suggested the possibility that expression of both EGFR and HER2 could be utilized for molecular targeted therapy in urinary bladder cancer. Interestingly, our western blot analyses revealed an enhanced expression of some of the EGFR-related intracellular signaling molecules in normal bladder tissue from experimental animals [Figure 1b]. The condition may cause a gradual reduction in the effectiveness of molecular targeted therapy and lead to resistance to treatment eventually. Perhaps, a combination of conventional management along with the targeted therapy could be beneficial. Nevertheless, it seems that both EGFR and HER2 expressions indicate a poor prognosis and thus hindering the activities of these growth factor receptors probably would help in the prognosis of bladder cancer patients. Different approaches to target these receptors have been devised such as tyrosine kinase inhibitors (e.g., gefitinib, lapatinib); monoclonal antibodies (e.g., cetuximab, trastuzumab); bispecific antibodies designed to target tumor antigens and cytotoxicity triggers; and monoclonal antibodies conjugated with cellular toxins, chemotherapeutic agents, or radioisotopes. Results of different ongoing studies on EGFR- or HER2-related targeted therapies in urinary bladder cancer may outline an effective treatment strategy in the near future.

REFERENCES

1. Consolidated report of population-based cancer registries 2001-2004. National Cancer Registry Programme (Indian Council of Medical Research), Bangalore, 2006.
2. Pleo M, Aben KK, Kiemeney LA. The present and future burden of urinary bladder cancer in the world. World J Urol 2009;27:289-93.
3. Parkin DM. The global burden of urinary bladder cancer. Scand J Urol Nephrol Suppl 2006;218:12-20.
24. Das BC, Sharma JK, Gopalkrishna V, Luthra UK. Analysis of polymerase chain reaction of the physical state of human papilloma type 16 DNA in cervical preneoplastic and neoplastic region. J Gen Virol 1992;73:2327-36.

25. Hedayat S, Jain N, Hussian SA, Mandal AK, Ray G, Shahid M, et al. Novel germline mutations in breast cancer susceptibility genes BRCA1, BRCA2 and p53 gene in breast cancer patients from India. Breast Cancer Res Treat 2004;88:177-186.

26. Ray A, Nikhata KJ, Grande JP, Cleary MP. Diet-induced obesity and mammary tumor development in relation to estrogen receptor status. Cancer Lett 2007;253:291-300.

27. Armitage P, Berry G, Matthews JN. Analysing means and proportions. In: Statistical methods in medical research. 4th ed. Oxford: Blackwell Science; 2002. p. 83-146.

28. Jain D, Ray A, Bahadur AK, Chaturvedi KJ, Sood R, Sharma S, et al. Status of epidermal growth factor receptors family in hormone-dependent carcinomas of the breast and prostate with reference to serum lipids and lipoproteins. Indian J Clin Biochem 2001;16:42-51.

29. Guo CC, Gomez E, Tamboli P, Bondaruk JE, Kamat A, Bassett R, et al. Squamous cell carcinoma of the urinary bladder: A clinicopathologic and immunohistochemical study of 16 cases. Hum Pathol 2009;40:1448-52.

30. Khaled HM, Bahnassy AA, Raafat AA, Zekri AR, Mabdouls MS, Mohktar NM. Clinical significance of altered nm23-H1, EGFR, RB and p53 expression in bladdarial bladder cancer. BMC Cancer 2009;9:32.

31. Wang X, Zhang S, Macleanen GT, Eble JN, Lopez-Beltran A, Yang YJ, et al. Epidermal growth factor receptor protein expression and gene amplification in small cell carcinoma of the urinary bladder. Clin Cancer Res 2007;13:953-7.

32. Kyoshima K, Oda Y, Kinukawa N, Naito S, Tsuneyoshi M. Overexpression of lamin5-gamma2 chain and its prognostic significance in urothelial carcinoma of urinary bladder: Association with expression of cyclooxygenase 2, epidermal growth factor receptor and human epidermal growth factor receptor 2. Hum Pathol 2005;36:522-30.

33. Cardillo MR, Castagna G, Memmo L, De Bernardinis E, Di Silverio F. Epidermal growth factor receptor, MUC-1 and MUC-2 in bladder cancer. J Exp Clin Cancer Res 2000;19:225-33.

34. Matsubara H, Yamada Y, Naruse K, Nakamura K, Aoki S, Taki T, et al. Potential for HER-2/neu molecular targeted therapy for invasive bladder carcinoma: Comparative study of immunohistochemistry and fluorescent in situ hybridization. Oncol Rep 2008;19:57-63.

35. Tapia C, Glaz K, Novotny H, Lugli A, Horric M, Seemayer CA, et al. Close association between HER-2 amplification and overexpression in human tumors of non-breast origin. Mod Pathol 2007;20:192-8.

36. Caner V, Turk NS, Duzcan F, Tufan NL, Kelten EC, Zencir S, et al. No strong association between HER-2/neu protein overexpression and gene amplification in high-grade invasive urothelial carcinomas. Pathol Oncol Res 2008;14:261-6.

37. Tsai YS, Tsai TS, Chow HY, Yang WH, Tong YC, Lin JS, et al. Prognostic values of p53 and HER-2/neu coexpression in invasive bladder cancer in Taiwan. Urol Int 2003;71:262-70.

38. de Piniereux G, Colin D, Vincent-Salomon A, Couturier J, Amsellem-Ouazana D, Beuzeboc P, et al. Confrontation of immunohistochemistry and fluorescent in situ hybridization for the assessment of HER-2/neu (c-erb-b2) status in uterine carcinoma. Virchows Arch 2004;444:415-9.

39. Coogan CL, Estrada CR, Kapur S, Bloom KJ. HER-2/neu overexpression and gene amplification in human transitional cell carcinoma of the bladder. Urology 2004;63:786-90.

40. Bermejo JL, Sundquist J, Hemminki K. Bladder cancer in cancer patients: population-based estimates from a large Swedish study. Br J Cancer 2009;101:1091-9.

41. Velcheri V, Govindan R. Metastatic cancer involving bladder: A review. Can J Urol 2007;14:3443-8.

42. Boysen T, Friborg J, Andersen A, Poulsen GN, Wohlforth J, Melbye M. The Inuit cancer pattern-the influence of migration. Int J Cancer 2008;122:2568-72.
43. de Vocht F, Sobala W, Wilczynska N, Peplonska B. Cancer mortality and occupational exposure to aromatic amines and inhalable aerosols in rubber tire manufacturing in Poland. Cancer Epidemiol 2009;33:94-102.
44. Sisci D, Surmacz E. Crosstalk between IGF signaling and steroid hormone receptors in breast cancer. Curr Pharm Des 2007;13:705-17.
45. Miyamoto H, Yang Z, Chen YT, Ishiguro H, Uemura H, Kubota Y, et al. Promotion of bladder cancer development and progression by androgen receptor signals. J Natl Cancer Inst 2007;99:558-68.
46. Teng J, Wang ZY, Jarrard DF, Bjorling DE. Roles of estrogen receptor alpha and beta in modulating urothelial cell proliferation. Endocr Relat Cancer 2008;15:351-64.
47. Metalli D, Lovat F, Tripodi F, Genua M, Xu SQ, Spinelli M, et al. The insulin-like growth factor receptor I promotes motility and invasion of bladder cancer cells through Akt- and mitogen-activated protein kinase-dependent activation of paxillin. Am J Pathol 2010;176:2997-3006.
48. Dovedi SJ, Davies BR. Emerging targeted therapies for bladder cancer: A disease waiting for a drug. Cancer Metastasis Rev 2009;28:355-67.
49. Chen CL, Cen L, Kohout J, Hutzen B, Chan C, Hsieh FC, et al. Signal transducer and activator of transcription 3 activation is associated with bladder cancer cell growth and survival. Mol Cancer 2008;7:78.
50. Díaz De Stahl T, Segersten U, Malmström PU. Molecular genetics of bladder cancer: An update. Minerva Urol Nefrol 2008;60:205-16.
51. Knowles MA, Platt FM, Ross RL, Hurst CD. Phosphatidylinositol 3-kinase (PI3K) pathway activation in bladder cancer. Cancer Metastasis Rev 2009;28:305-16.
52. Black PC, Dinney CP. Growth factors and receptors as prognostic markers in urothelial carcinoma. Curr Urol Rep 2008;9:55-61.

How to cite this article: Naik DS, Sharma S, Ray A, Hedau S. Epidermal growth factor receptor expression in urinary bladder cancer. Indian J Urol 2011;27:208-14.

Source of Support: Nil, Conflict of Interest: None declared.